Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

Next-generation therapeutic siRNA to target point mutation drivers of a rare cancer

FY 2024-25

Summary
Recent breakthroughs have opened the way for the therapeutic use of small interfering RNA (siRNA). siRNA function as guides in RNA interference (RNAi), a natural mechanism that regulates gene expression, and can also be co-opted to target and degrade messenger RNA (mRNA). This process can function with single-nucleotide precision and can be further optimized through chemical modifications to stabilize and enhance the siRNAs. Concurrently, lipid nanoparticles (LNPs) have solved major delivery barriers by protecting siRNAs from extracellular degradation, facilitating cellular uptake, and preventing innate immune activation. These innovations position siRNA therapeutics as a promising approach for treating rare and aggressive cancers, such as diffuse midline gliomas (DMG). DMG currently have limited treatment options and are driven by a point mutation in the H3 histone protein (H3K27M), where lysine 27 is replaced by methionine. This proposal will develop and test the potential of siRNA-based therapeutics in targeting the point-mutation causing this rare cancer. First, we will screen a library of siRNA candidates targeting H3K27M in cell culture, using cell killing assays to identify the most effective sequences and backbone chemistries. The top candidates will be advanced to in vivo studies. Second, these siRNAs will be formulated with LNPs and evaluated in mouse models bearing H3K27M tumors using intra-tumoral and intra-cerebroventricular injections. Comprehensive characterization of the targeting efficiency will be conducted, evaluating protein down-regulation, tumor regression, and safety. This project not only provides a framework for treating cancers driven by point mutations, but will open new applications in precision medicine for other diseases.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530234
Name
Tector Simon D
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Next-generation therapeutic siRNA to target point mutation drivers of a rare cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Diffuse Midline Glioma; Epigenetics; Histone; Lipid Nanoparticles; Pediatric High Grade Glioma; Point Mutation; Rna-Induced Silencing Complex (Risc); Rnai; Sirna
Abstract
Recent breakthroughs have opened the way for the therapeutic use of small interfering RNA (siRNA). siRNA function as guides in RNA interference (RNAi), a natural mechanism that regulates gene expression, and can also be co-opted to target and degrade messenger RNA (mRNA). This process can function with single-nucleotide precision and can be further optimized through chemical modifications to stabilize and enhance the siRNAs. Concurrently, lipid nanoparticles (LNPs) have solved major delivery barriers by protecting siRNAs from extracellular degradation, facilitating cellular uptake, and preventing innate immune activation. These innovations position siRNA therapeutics as a promising approach for treating rare and aggressive cancers, such as diffuse midline gliomas (DMG). DMG currently have limited treatment options and are driven by a point mutation in the H3 histone protein (H3K27M), where lysine 27 is replaced by methionine. This proposal will develop and test the potential of siRNA-based therapeutics in targeting the point-mutation causing this rare cancer. First, we will screen a library of siRNA candidates targeting H3K27M in cell culture, using cell killing assays to identify the most effective sequences and backbone chemistries. The top candidates will be advanced to in vivo studies. Second, these siRNAs will be formulated with LNPs and evaluated in mouse models bearing H3K27M tumors using intra-tumoral and intra-cerebroventricular injections. Comprehensive characterization of the targeting efficiency will be conducted, evaluating protein down-regulation, tumor regression, and safety. This project not only provides a framework for treating cancers driven by point mutations, but will open new applications in precision medicine for other diseases.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tector, Simon D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~